Latest Funding News

Challenger Limited reported a solid 4% increase in total Life sales to $2.5 billion in Q1 FY26, buoyed by strong annuity sales and strategic partnerships. The company reaffirmed its FY26 earnings guidance while highlighting upcoming regulatory changes expected to benefit the sector.

AuMEGA Metals has identified a significant new gold corridor at Cape Ray West, marked by high-grade gold-in-till anomalies linked to an untested felsic intrusive complex. The company is preparing for fully funded drilling in late 2025 to explore these promising targets.

European Lithium Limited signals a likely change to the timetable for its replacement options offer as 208 million options approach expiry in November. Investors await updated details amid potential capital structure implications.

EMVision Medical Devices’ latest Share Purchase Plan has attracted applications exceeding its initial $1 million target, with limited oversubscription capacity remaining ahead of the October 23 closing date.

QPM Energy has initiated funding under its $113.7 million Master Lease Agreement with Macquarie Bank and triggered equipment delivery from GE Vernova, marking a key milestone in its project development.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Dominion Investment Group Limited has announced an offer of up to $500 million in unsecured, deferrable, redeemable floating rate notes, aiming to provide investors with monthly income and ASX listing under ticker DMNHA.

ActivEX Limited has completed a significant $800,000 share placement to True Creation Limited, aiming to strengthen its financial footing and advance exploration projects.

Southern Cross Gold Consolidated Ltd. reported a net loss of $925,512 for Q1 2026, alongside significant progress in its Australian gold-antimony projects and key corporate milestones including TSX main board graduation.

Aerometrex reports a robust first quarter with a 42.75% annualised rise in MetroMap subscription revenue, a significant 3D project contract in the US, and a 52% jump in LiDAR sales, underpinning its strategic momentum.

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Bod Science reports a $576k cash outflow in Q1 FY2026 amid ongoing administration and delays in Biortica audit completion. The company plans a shareholder vote in November to approve its acquisition of Biortica and exit from administration.